




The relative strengths and weaknesses of Immune Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Immune Pharmaceuticals INC compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 3.0% points. The greatest weakness of Immune Pharmaceuticals INC is the variable Stockholders Equity, reducing the Economic Capital Ratio by 117% points.

The company's Economic Capital Ratio, given in the ranking table, is 59%, being 175% points below the market average of 234%.

Input Variable	Value in 1000 USD
Assets, Current	6,737
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,237
Liabilities, Non-Current	365
Other Assets	664
Other Compr. Net Income	299
Other Expenses	696
Other Liabilities	12,065
Other Net Income	-1,599
Other Revenues	944
Property and Equipment	120
Research and Development	7,853
Selling, General and Administrative Expense	6,452

Output Variable	Value in 1000 USD
Assets	7,521
Liabilities	24,667
Expenses	15,001
Revenues	944
Stockholders Equity	-17,146
Net Income	-15,656
Comprehensive Net Income	-15,506
BaseVar	25,016
ECR before LimitedLiability	-329%
Economic Capital Ratio	59%